1,721,553 research outputs found

    Preface

    No full text

    Fig. 6 in Iranian Salvia species: A phytochemical and pharmacological update

    No full text
    Fig. 6. (continued).Published as part of Askari, Sayyedeh Fatemeh, Avan, Razieh, Tayarani-Najaran, Zahra, Sahebkar, Amirhossein & Eghbali, Samira, 2021, Iranian Salvia species: A phytochemical and pharmacological update, pp. 1-24 in Phytochemistry (112619) 183 on page 16, DOI: 10.1016/j.phytochem.2020.112619, http://zenodo.org/record/829175

    Current and emerging treatments for neonatal sepsis

    No full text
    Introduction: Mortality due to sepsis is still prevalent, peaking at extreme ages of life including infancy. Despite many efforts, the peculiarity of the infant immune system has limited further advances in its treatment. Indeed, neonates experience a dramatic physiological transition from immune tolerance to the maternal antigens to functional maturity. Such a transition is extremely dynamic, as is the pathophysiology of infant sepsis, which is dependent on many infant, maternal, and environmental factors.Areas covered: In this review, the authors critically update and summarize the current paradigm of immunomodulation in infant sepsis. They confirm how exogenous stimulation of the immune system through intravenous immunoglobulin, colony stimulating factors, and granulocyte transfusion have failed to impact on the prognosis of infant sepsis. They also strongly support the beneficial effects of supplementation/replacement therapies with products naturally contained within maternal milk as well as antioxidant compounds.Expert opinion: Breastfeeding is beneficial against sepsis. Knowledge of the neonatal immune system is indeed too limited to effectively strengthen immune response by exogenous interventions, especially in preterm and low-birth-weight infants. Awareness of this limitation should pave the way for future studies (e.g. gender- and omics-based) aimed at better characterizing the infant immune system and promoting a more tailored approach

    Fig. 4 in Iranian Salvia species: A phytochemical and pharmacological update

    No full text
    Fig. 4. The structures of sesterterpenoids isolated from Iranian Salvia species.Published as part of Askari, Sayyedeh Fatemeh, Avan, Razieh, Tayarani-Najaran, Zahra, Sahebkar, Amirhossein & Eghbali, Samira, 2021, Iranian Salvia species: A phytochemical and pharmacological update, pp. 1-24 in Phytochemistry (112619) 183 on page 10, DOI: 10.1016/j.phytochem.2020.112619, http://zenodo.org/record/829175

    Fig. 5 in Iranian Salvia species: A phytochemical and pharmacological update

    No full text
    Fig. 5. (continued).Published as part of Askari, Sayyedeh Fatemeh, Avan, Razieh, Tayarani-Najaran, Zahra, Sahebkar, Amirhossein & Eghbali, Samira, 2021, Iranian Salvia species: A phytochemical and pharmacological update, pp. 1-24 in Phytochemistry (112619) 183 on page 13, DOI: 10.1016/j.phytochem.2020.112619, http://zenodo.org/record/829175

    Fig. 7 in Iranian Salvia species: A phytochemical and pharmacological update

    No full text
    Fig. 7. Pharmacological effects of Iranian Salvia species.Published as part of Askari, Sayyedeh Fatemeh, Avan, Razieh, Tayarani-Najaran, Zahra, Sahebkar, Amirhossein & Eghbali, Samira, 2021, Iranian Salvia species: A phytochemical and pharmacological update, pp. 1-24 in Phytochemistry (112619) 183 on page 20, DOI: 10.1016/j.phytochem.2020.112619, http://zenodo.org/record/829175

    Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials

    No full text
    Decreased activity of the enzyme paraoxonase-1 (PON1) has been demonstrated in cardiovascular diseases. Statins, the forefront of pharmacotherapy for dyslipidemia, have been shown to enhance PON1 activity but clinical findings have not been conclusive
    corecore